Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed the Federal Trade Commission has been investigating the telehealth ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock dropped 2.6% on Friday following reports that the Federal Trade Commission has been investigating the telehealth company's business practices for ...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than ...

Telehealth company Hims & Hers Health’s ($HIMS) business practices have been under investigation by the U.S. Federal Trade ...

The US health sector is bustling with activity. Key developments include an FTC investigation into Hims & Hers' practices, ...

For more than a year, the Federal Trade Commission has been investigating Hims & Hers Health Inc.’s business practices, including whether it has made it too hard for customers to cancel subscriptions, ...

The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers regarding its advertising and ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Current health news highlights include UK investor backing in Assura's acquisition by PHP, Novo Nordisk's legal affairs over Wegovy drug sales, and Apollo Hospitals' increased AI investments. The CDC ...

In Q2 2025, Hims & Hers reported adjusted earnings of $0.17 per share, topping estimates of $0.15. Revenue rose 73% year-over ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...